Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus

Effect of Incretin-related Drugs on Energy and Contents of Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01568125

Enrollment

100

Registered

2012-04-02

Start date

2010-01-31

Completion date

2014-01-31

Last updated

2012-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

It is well known that incretin, particular GLP-１enhances satiety and reduces energy intake in controlling appetite and dietary in humans (Flint A, et al. Gutzwiller JP et al.). Recently, incretin-based therapy has been attracted a lot of interest (Hare KJ, Knop FK). However, it is not clear how the incretin-based therapy affects energy and content of dietary intake in patients with type 2 diabetes mellitus (T2DM). Previously, the investigators reported the amount of energy and content of dietary intake in type 2 diabetic Japanese patients with more than 10 years of long time duration after discovery using questionnaire (Inoue K et al.) and the patients were impaired a secretion of active GLP-1 (Kamoi et al). The investigators examine whether the incretin-based therapy effects on the energy and content of dietary intake in the same patients before and one year after administration of incretin-related drugs using the same method previously (Inoue K et al.).

Interventions

DRUGIncretin-related drugs

DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 95 Years

Healthy volunteers

Inclusion criteria

* Japanese patients with T2DM without incretin-based therapy, who participated to examine the energy and content of intake using questionnaire reported previously.

Exclusion criteria

* Patients with a serious complication in the heart, liver or kidney * Pregnant or possibly pregnant patients or lactating patients * Patients complicated with a malignant tumor at present. * Patients participating in other clinical study. * Other than the above, patients judged inappropriate as the subjects of this study by the investigator

Design outcomes

Primary

Measure	Time frame
HbA1c	one year

Secondary

Measure	Time frame
BMI	One year
Calory of dietary intake	One year
Content of dietary intake	One year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026